European guideline for the management of genital herpes, 2010

International Journal of STD and AIDS

Volumn 22, Issue 1, 2011, Pages 1-10

  Patel, R ^a   Alderson, S ^b   Geretti, A ^c   Nilsen, A ^d   Foley, E ^a   Lautenschlager, S ^e   Green, J ^f   Van Der Meijden, W ^g   Gomberg, M ^h   Moi, H ⁱ  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BERGEN   (Norway)

^e Dermatologisches Ambulatorium Triemli   (Switzerland)

^f CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

ⁱ UNIVERSITY OF OSLO   (Norway)

Author keywords

Aciclovir; Diagnosis; Europe; Famciclovir; Guideline; Herpes simplex; Management; Transmission; Treatment; Valaciclovir

Indexed keywords

ACICLOVIR; BENZOCAINE; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; IMIQUIMOD; IMMUNOGLOBULIN G; LIDOCAINE; PETROLATUM; SODIUM CHLORIDE; TRIFLURIDINE; VALACICLOVIR;

ABSENCE OF SIDE EFFECTS; ANTIGEN DETECTION; ANTIVIRAL THERAPY; BATH; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CONDOM; DISEASE CARRIER; DNA DETERMINATION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GENITAL HERPES; HEMOLYTIC UREMIC SYNDROME; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOFLUORESCENCE TEST; INFECTION PREVENTION; INFECTION RISK; LABOR ONSET; MICROANGIOPATHY; NAUSEA; NUCLEIC ACID AMPLIFICATION; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RECURRENT INFECTION; REVIEW; SECOND TRIMESTER PREGNANCY; SEROLOGY; SEROPREVALENCE; SEXUAL COUNSELING; SEXUAL TRANSMISSION; SEXUALITY; SHORT COURSE THERAPY; SUPERINFECTION; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; VAGINAL DELIVERY; VIRUS CULTURE; VIRUS DETECTION; VIRUS ISOLATION; VIRUS SHEDDING; VIRUS TRANSMISSION; VIRUS TYPING; WESTERN BLOTTING;

FEMALE; HERPES GENITALIS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 79952270580     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2010.010278     Document Type: Review

References (89)

1. Casper C, Wald A. Condom use and the prevention of genital herpes acquisition. Herpes 2002;9:10-4 (Pubitemid 37489856)
2. Wald A, Langenberg AGM, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005;143:707-13
3. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007;370:2127-37 (Pubitemid 350296304)
4. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992;326:1533-9
5. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003;188:1345-51 (Pubitemid 37433705)
6. Ramaswamy M, McDonald C, Smith M, et al. Diagnosis of genital herpes by real-time PCR in routine clinical practice. Sex Transm Infect 2004;80:406-10 (Pubitemid 39389562)
7. Van Doornum GJ, Guldemeester J, Osterhaus AD, Niesters HG. Diagnosing herpesvirus infections by real-time amplification and rapid culture. J Clin Microbiol 2003;41:576-80 (Pubitemid 36184164)
8. Geretti AM. Genital herpes. Sex Transm Infect 2006;82(Suppl 4):v31-4
9. Verano L, Michalski FJ. Herpes simplex virus antigen direct detection in standard virus transport medium by Du Pont Herpchek enzyme-linked immunosorbent assay. J Clin Microbiol 1990;28:2555-8 (Pubitemid 20353538)
10. Slomka MJ, Emery L, Munday PE, Moulsdale M, Brown DW. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. J Med Virol 1998;55:177-83 (Pubitemid 28221623)
11. Cone RW, Swenson PD, Hobson AC, Remington M, Corey L. Herpes simplex virus detection from genital lesions: a comparative study using antigen detection (HerpChek) and culture. J Clin Microbiol 1993;31:1774-6 (Pubitemid 23182574)
12. Munday PE, Vuddamalay J, Slomka MJ, et al. Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes. Sex Transm Infect 1998;74:175-8
13. Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999;12:1-8 (Pubitemid 29055950)
14. Malkin JE. Herpes simplex virus. Who should be tested. Herpes 2002;9:31
15. Copas AJ, Cowan FM, Cunningham AL, Mindel A. An evidence based approach to testing for antibody to herpes simplex virus type 2. Sex Transm Infect 2002;78:430-4 (Pubitemid 36020817)
16. Corey L, Wald A, Patel R, et al. Once daily valaciclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20 (Pubitemid 38032179)
17. Ramaswamy M, McDonald C, Sabin C, Tenant-Flowers M, Smith M, Geretti AM. The epidemiology of genital infection with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in genitourinary medicine attendees in inner London. Sex Transm Infect 2005;81:306-8 (Pubitemid 41160734)
18. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509-15 (Pubitemid 27352016)
19. Rouse DJ, Stringer JSA. An appraisal of screening for maternal type-specific herpes simplex antibodies to prevent neonatal herpes. Am J Obstet Gynecol 2000;183:400-6 (Pubitemid 30651088)
20. Tita AT, Grobman WA, Rouse DJ. Antenatal herpes serologic screening: an appraisal of the evidence. Obstet Gynecol 2006;108:1247-53 (Pubitemid 44665424)
21. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52 (Pubitemid 34043015)
22. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 2006;43:347-56 (Pubitemid 44078908)
23. Ramaswamy M, Geretti AM. Interactions and management issues in HSV and HIV coinfection. Expert Rev Infect Ther 2007;5:231-43 (Pubitemid 46681742)
24. Drake AL, John-Stewart GC, Wald A, et al. Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007;109:403-9 (Pubitemid 46197434)
25. Bollen LJ, Whitehead SJ, Mock PA, et al. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? AIDS 2008;22:1169-76
26. Chen KT, Tuomala RE, Chu C, et al. No association between antepartum serologic and genital tract evidence of herpes simplex virus-2 coinfection and perinatal HIV-1 transmission. Am J Obstet Gynecol 2008;198:399.e1-5
27. Ashley RL. Performance and use of HSV type-specific serology test kits. Herpes 2002;9:38-45 (Pubitemid 37486606)
28. Ashley RL, Benedetti J, Corey L. Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. J Med Virol 1985;17:153-66 (Pubitemid 16223614)
29. Ashley RL. Type-specific antibodies to HSV-1 and 2: review of methodology. Herpes 1998;5:33-8 (Pubitemid 29007968)
30. Smith JS, Bailey RC, Westreich DJ, et al. Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing. Sex Transm Infect 2009;85:92-6
31. Gopal R, Gibbs T, Slomka MJ, et al. A monoclonal blocking EIA for herpes simplex virus type 2 antibody: validation for seroepidemiological studies in Africa. J Virol Methods 2000;87:71-80 (Pubitemid 30345677)
32. Morrow RA, Friedrich D, Krantz E. Performance of the Focus and Kalon enzyme-linked immunosorbent assays for antibodies to herpes simplex virus type 2 glycoprotein G in culture-documented cases of genital herpes. J Clin Microbiol 2003;41:5212-4
33. Van E, Buve A, et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol 2004;42:2961-5
34. Golden MR, Ashley-Morrow R, Swenson P, Hogrefe WR, Handsfield HH, Wald A. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis 2005;32:771-7 (Pubitemid 41752565)
35. Morrow RA, Friedrich D, Meier A, Corey L. Use of 'biokit HSV-2 Rapid Assay' to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis 2005;5:84
36. Ashley R, Krantz E, Friedrich D, Wald A. Clinical correlates of index values in the focus HerpeSelect ELISA for antibodies to herpes simplex virus type 2 (HSV-2). J Clin Virol 2006;36:141-5
37. Nascimento MC, Ferreira S, Sabino E, et al. Performance of the HerpeSelect (Focus) and Kalon enzyme-linked immunosorbent assays for detection of antibodies against herpes simplex virus type 2 by use of monoclonal antibody-blocking enzyme immunoassay and clinicovirological reference standards in Brazil. J Clin Microbiol 2007;45:2309-11 (Pubitemid 47203817)
38. LeGoff J, Mayaud P, Gresenguet G, et al. Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. J Clin Microbiol 2008;46:1914-8 (Pubitemid 351831819)
39. Gamiel JL, Tobian AA, Laeyendecker OB, et al. Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. Clin Vaccine Immunol 2008;15:888-90 (Pubitemid 351967018)
40. Smith JS, Bailey RC, Westreich DJ, et al. Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing. Sex Transm Infect 2009;85:92-6
41. Laderman EI, Whitworth E, Dumaual E, et al. Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood. Clin Vaccine Immunol 2008;15:159-63 (Pubitemid 351966545)
42. Morrow R, Friedrich D. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect 2006;12:463-9
43. Corey L, Benedetti J, Critchlow C, et al. Treatment of primary first-episode genital herpes simplex virus infections with aciclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983;12(Suppl B):79-88 (Pubitemid 14228002)
44. Fife KH, Barbarash RA, Rudolph T, DeGregorio B, Roth R. Valaciclovir versus aciclovir in the treatment of first-episode genital herpes infection. Results of an international multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997;24:481-6
45. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76-80 (Pubitemid 36091604)
46. Weightman W, Turner T. Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature. Contact Dermatitis 1998;39:265
47. Carney O, Ross E, Bunker C, Ikkos G, Mindel A. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourinary Med 1994;70:40-5 (Pubitemid 24101412)
48. Patel R, Tyring S, Price MJ, et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999;75:398-402 (Pubitemid 30056236)
49. Green J, Kocsis A. Psychological factors in recurrent genital herpes. Genitourinary Med 1997;73:253-9
50. Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral aciclovir in the treatment of initial and recurrent genital herpes. Lancet 1982;ii:571-3 (Pubitemid 12049485)
51. Spruance SL, Tyring TK, DeGregorio B, Miller C, Beutner K and the Valaciclovir study group. A large-scale, placebo controlled, dose ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996;156:1729-35
52. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD, for the Canadian Famciclovir Study. Patient-initiated, twice daily, oral famciclovir for early recurrent genjnital herpes: a randomized, double-blind multicenter trial. JAMA 1996;276:44-9
53. Spruance SL, Overall JC, Kern ER, et al. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med 1977:69-75 (Pubitemid 8122841)
54. Wald A, Carrell D, Remington M, et al. Two-day regiment of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944-8 (Pubitemid 34229763)
55. Bodsworth N, Bloch M, McNulty A. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sexual Health 2008;5:219-25
56. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of aciclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944-8 (Pubitemid 34229763)
57. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8-13 (Pubitemid 41832073)
58. Abudalu M, Tyring S, Koltun W, Bodsworth N, Hamed K. Single-day patient-initiated famciclovir therapy versus 3-day valaciclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008;47:651-8
59. Leone PA, Trottier S, Miller JM. Valaciclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958-62 (Pubitemid 34229765)
60. Strand A, Patel R, Wulf HC, Coates KM and The International Valaciclovir Study Group. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex Transm Infect 2002;78:435-9
61. Mertz GJ, Jones CC, Mills J, et al. Long-term aciclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 1988;260:201-6
62. Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P. Dosage and safety of long-term suppressive aciclovir therapy for recurrent genital herpes. Lancet 1988;331:926-8 (Pubitemid 18096755)
63. Lebrun-Vignes B, et al. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol 2007;57:238-46 (Pubitemid 47048864)
64. Geretti AM. Genital herpes. Sex Transm Infect 2006;82 Suppl 4:v31-4
65. Corey L, Wald A, Patel R, et al. Once-daily valaciclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20 (Pubitemid 38032179)
66. Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV infected individuals. AIDS 2000;14:1211-17 (Pubitemid 30420665)
67. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ. International Valaciclovir HSV Study Group. Int J STD AIDS 2002;13:12-21
68. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998;128:21-8 (Pubitemid 28016714)
69. Youle MS, Gazzard BG, Johnson MA, et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebocontrolled study. AIDS 1994;8:641-9 (Pubitemid 24126122)
70. Cooper DA, Pehrson PO, Pedersen C, et al. The efficacy and safety of zidovudine alone or as cotherapy with aciclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind, randomized trial. AIDS 1993;7:197-207 (Pubitemid 23091289)
71. Bell WB, Chulay JD, Feinberg JE. Manifestations resembling thrombomicroangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997;76:369-80
72. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009;23:461-9
73. Lingappa JR, Baeten JM, Wald A. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010;375:824-33
74. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 2003;102:1396-403 (Pubitemid 37518425)
75. Watts DH, Brown ZA, Money D, et al. A doubleblind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of Herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003;188:836-43 (Pubitemid 36332461)
76. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002;10:71-7
77. Brocklehurst P, Kinghorn G, Carney O, et al. A randomised placebo-controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol 1998;105:275-80 (Pubitemid 28123575)
78. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996;87:69-73 (Pubitemid 26015954)
79. Braig S, Luton D, Sibony O, et al. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol Reprod Biol 2001;96:55-8 (Pubitemid 32331850)
80. Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplx virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev 2008;1:CD004946
81. Gardella C, Brown ZA, Wald A, et al. Poor correlation between genital lesions and detection of herpes simplex virus in women in labor. Obstet Gynecol 2005;106:268-74 (Pubitemid 41023262)
82. Chen KT, Segu M, Lumey LH, et al. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol 2005;106:1341-8 (Pubitemid 41668955)
83. Drake AL, John-Stewart GC, Wald A, et al. Herpes simplex virus type 2 and the risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007;10:403-9 (Pubitemid 46197434)
84. Chen KT, Tuomala RE, Chu C, et al. No association between antepartum serologic and genital tract evidence of herpes simplex virus-2 coinfection and perinatal HIV-1 transmission. Am J Obstet Gynecol 2008;198:399
85. Chen KT, Tuomala RE, Chu C, et al. No association between antepartum serologic and genital tract evidence of herpes simplex virus-2 coinfection and perinatal HIV-1 transmission. Am J Obstet Gynecol 2008;198:p399.e1-5
86. Poeran J, Wildschut H, Gaytant M, Galama J, Steegers E, van der Meijden W. The incidence of neonatal herpes in The Netherlands. J Clin Virol 2008;42:321-5
87. Acyclovir and Valacyclovir in Pregnancy Registry final report. April 1999. See http://pregnancyregistry.gsk.com/acyclovir.html (last accessed 1 December 2010)
88. Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsay PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol 2006;194:774-8
89. Sheffield JS, Hill JB, Hollier LM, et al. Valacylovir prophylaxis to prevent recurrent herpes at delivery: a randomised clinical trial. Obstet Gynecol 2006;108:141-7 (Pubitemid 44336857)